Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EBT (2022 - 2025)

Historic EBT for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to -$6.0 million.

  • PAVmed's EBT changed N/A to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $28.4 million for FY2024, which is 13586.41% up from last year.
  • As of Q3 2025, PAVmed's EBT stood at -$6.0 million.
  • PAVmed's 5-year EBT high stood at $18.6 million for Q1 2025, and its period low was -$29.9 million during Q3 2022.
  • Its 4-year average for EBT is -$15.3 million, with a median of -$18.2 million in 2023.
  • In the last 5 years, PAVmed's EBT tumbled by 1314.62% in 2023 and then surged by 20059.96% in 2025.
  • PAVmed's EBT (Quarter) stood at -$24.6 million in 2022, then rose by 29.16% to -$17.4 million in 2023, then surged by 106.56% to $1.1 million in 2024, then tumbled by 626.36% to -$6.0 million in 2025.
  • Its EBT was -$6.0 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $18.6 million in Q1 2025.